Earnings 31 Mar 2026: GKB.BO GKB Ophthalmics (BSE) pre-market watch margins, cash

GKB.BO stock enters pre-market trade on 31 Mar 2026 as GKB Ophthalmics prepares to release Q4 results. Investors will watch margins, cash per share INR 27.01 and EPS of -5.01. The company trades on BSE at INR 52.50, with a one-year range of INR 45.25 to INR 91.70. Today’s report may explain the recent slide from the 50-day average of INR 56.43 and guide short-term trading ahead of volume updates.

Earnings preview: what GKB.BO stock report may show

GKB Ophthalmics will likely highlight revenue per share of INR 298.17 and continued pressure on net income. Expect commentary on cost control after gross margin compressed last year. Management guidance on exports and lens demand will shape the market reaction. Analysts will monitor any one-off items that affect EPS and cash conversion.

Quarterly financials and key metrics for GKB.BO stock

Current market price is INR 52.50 with market capitalization INR 264,630,450.00. The trailing EPS is -5.01 and PE is -10.48, reflecting a loss-making period. Price to book is attractive at 0.50 while price to sales is 0.18. Inventory days are long at 182.79, and receivables days stand at 71.75, which can pressure working capital.

Meyka AI rates GKB.BO with a score out of 100 and analyst view

Meyka AI rates GKB.BO with a score out of 100: 66.15 / 100 — Grade B, Suggestion: HOLD. This grade factors S&P 500 comparison, sector and industry peers, financial growth, key metrics, forecasts, and analyst consensus. Market consensus shows weak fundamental scores but reasonable book value, so the stock sits between value appeal and earnings risk.

Technical setup and trading signals for GKB.BO stock

Technical indicators show neutral to weak momentum. RSI is 44.18 and MACD histogram is -0.50. Bollinger middle band sits at INR 56.88 and lower band at INR 51.02, giving immediate support near current price. ADX at 32.86 signals a strong trend, currently to the downside. Volume is light at 1,009.00 shares versus average 3,699.00.

Price forecasts, targets and Meyka AI outlook for GKB.BO stock

Meyka AI’s forecast model projects a monthly target of INR 46.84, a quarterly target of INR 32.26, and a 12-month target of INR 37.52. Versus the current INR 52.50, the 12-month target implies -28.53% downside. These are model-based projections and not guarantees. Traders may use the INR 46.84 level as a near-term reference and INR 32.26 as a downside scenario.

Risks and opportunities in the Healthcare sector for GKB.BO stock

GKB Ophthalmics operates in Healthcare, a sector that has outperformed on margins but is dispersing this quarter. Company-specific risks include weak interest coverage at -0.31 and net debt to EBITDA near 3.71. Opportunities include low PB of 0.50, tangible book value per share INR 113.21, and steady demand for optical lenses in export markets.

Final Thoughts

GKB.BO stock trades at INR 52.50 in pre-market hours ahead of Q4 results on 31 Mar 2026. The report will likely focus on margin recovery, inventory reduction, and cash conversion. Fundamentals show a strong book value per share INR 113.57 but negative EPS -5.01 and constrained interest coverage. Meyka AI’s forecast model projects a 12-month target of INR 37.52, implying -28.53% versus today’s price. That gap reflects earnings risk despite a low PB ratio and tangible assets. Use the near-term INR 46.84 and the quarterly INR 32.26 model levels for scenarios. These forecasts are model-based projections and not guarantees. For real-time updates see the Reuters company page and our Meyka stock page for GKB.BO

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.